These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 6825996)
1. Does intercurrent hepatitis have a beneficial effect on the course of Crohn's disease? Vantrappen G; Coremans G; Janssens J; Rutgeerts P Gastroenterology; 1983 Apr; 84(4):843-5. PubMed ID: 6825996 [TBL] [Abstract][Full Text] [Related]
2. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601 [TBL] [Abstract][Full Text] [Related]
3. Testing for course patterns in Crohn's disease using clustering analysis. Beaugerie L; Le Quintrec Y; Paris JC; Godchaux JM; Saint-Raymond A; Schmitz J; Ricour C; Haddak M; Diday E Gastroenterol Clin Biol; 1989 Dec; 13(12):1036-41. PubMed ID: 2625182 [TBL] [Abstract][Full Text] [Related]
4. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: Retrospective study. Astegiano M; Pagano N; Sapone N; Simondi D; Bertolusso L; Bresso F; Demarchi B; Pellicano R; Bonardi R; Marconi S; Rizzetto M Biomed Pharmacother; 2007 Jul; 61(6):370-6. PubMed ID: 17399941 [TBL] [Abstract][Full Text] [Related]
11. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. Gao Q; Hogezand RA; Lamers CB; Verspaget HW Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330 [TBL] [Abstract][Full Text] [Related]
12. Perineal Crohn's disease: an indicator of poor prognosis and potential proctectomy. Figg RE; Church JM Dis Colon Rectum; 2009 Apr; 52(4):646-50. PubMed ID: 19404069 [TBL] [Abstract][Full Text] [Related]
13. Severe gastrointestinal bleeding in Crohn's disease. Veroux M; Angriman I; Ruffolo C; Barollo M; Buffone A; Madia C; Caglià P; Fiamingo P; D'Amico D Ann Ital Chir; 2003; 74(2):213-5; discussion 216. PubMed ID: 14577120 [TBL] [Abstract][Full Text] [Related]
14. Clinical and virological improvement of hepatitis B virus-related or hepatitis C virus-related chronic hepatitis with concomitant hepatitis A virus infection. Sagnelli E; Coppola N; Pisaturo M; Pisapia R; Onofrio M; Sagnelli C; Catuogno A; Scolastico C; Piccinino F; Filippini P Clin Infect Dis; 2006 Jun; 42(11):1536-43. PubMed ID: 16652310 [TBL] [Abstract][Full Text] [Related]
15. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Berni Canani R; Terrin G; Borrelli O; Romano MT; Manguso F; Coruzzo A; D'Armiento F; Romeo EF; Cucchiara S Dig Liver Dis; 2006 Jun; 38(6):381-7. PubMed ID: 16301010 [TBL] [Abstract][Full Text] [Related]
16. Crohn's disease-induced non-alcoholic fatty liver disease (NAFLD) sensitizes for severe acute hepatitis B infection and liver failure. Canbay A; Bechmann LP; Best J; Jochum C; Treichel U; Gerken G Z Gastroenterol; 2006 Mar; 44(3):245-8. PubMed ID: 16514570 [TBL] [Abstract][Full Text] [Related]
17. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Korzenik JR; Dieckgraefe BK Aliment Pharmacol Ther; 2005 Feb; 21(4):391-400. PubMed ID: 15709989 [TBL] [Abstract][Full Text] [Related]
18. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Wörns MA; Teufel A; Kanzler S; Shrestha A; Victor A; Otto G; Lohse AW; Galle PR; Höhler T Am J Gastroenterol; 2008 Jan; 103(1):138-46. PubMed ID: 17970833 [TBL] [Abstract][Full Text] [Related]
19. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report. van der Hagen SJ; Baeten CG; Soeters PB; Russel MG; Beets-Tan RG; van Gemert WG Dis Colon Rectum; 2005 Apr; 48(4):758-67. PubMed ID: 15750797 [TBL] [Abstract][Full Text] [Related]
20. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]